URGN
$33.91-0.38%
UroGen Pharma Ltd.Stock · HealthcareRussell 2000 · 0.05% of IWMNasdaq Composite · 0.004% of ONEQRussell 3000 · 0.003% of IWV
UroGen Pharma Ltd. total returns by year (including dividends)
As of market close, Oct 27, 2026
UroGen Pharma Ltd. total returns by year (2018–2026)#
Calendar-year returns with each year's path and its dividend contribution (dividend return = total minus price return). Every year has a direct link you can bookmark or share.
| Year | Start price | End price | Path | Dividend | Total return |
|---|---|---|---|---|---|
| 2026YTD | $23.42 | $33.91 | 0.0% | +44.8% | |
| 2025 | $10.65 | $23.42 | 0.0% | +119.9% | |
| 2024 | $15.00 | $10.65 | 0.0% | -29.0% | |
| 2023 | $8.87 | $15.00 | 0.0% | +69.1% | |
| 2022 | $9.51 | $8.87 | 0.0% | -6.7% | |
| 2021 | $18.02 | $9.51 | 0.0% | -47.2% | |
| 2020 | $33.37 | $18.02 | 0.0% | -46.0% | |
| 2019 | $43.06 | $33.37 | 0.0% | -22.5% | |
| 2018 | $37.21 | $43.06 | 0.0% | +15.7% |
- Annualized
- +7.1%
- 2018–2026
- Average year
- +6.7%
- 8 full years
- Best year
- +119.9%
- 2025
- Worst year
- -47.2%
- 2021
- Positive years
- 3/8
- 38% up
Annualized (CAGR)
+7.1%
2018–2026
Average year
+6.7%
8 full years
Best year
+119.9%
2025
Worst year
-47.2%
2021
Positive years
3/8
38% up
Total return by period#
Annual
-100%-50%0%50%100%
2018+16%'18
2019-23%'19
2020-46%'20
2021-47%'21
2022-6.7%'22
2023+69%'23
2024-29%'24
2025+120%'25
2026+45%'26
Methodology#
Total returns, dividends reinvested, measured on URGN. Annualized return is the compound annual growth rate; the current year is year-to-date. Past performance does not predict future returns.
FAQ#
- What is UroGen Pharma Ltd.'s average annual return?
- Since 2018, UroGen Pharma Ltd. (URGN) has returned about 7.1% a year (the compound annual growth rate) and an average calendar-year return of 6.7%.
- What were UroGen Pharma Ltd.'s best and worst years?
- Over 2018–2026, the best year was 2025 (+119.9%) and the worst was 2021 (-47.2%).
- How often is UroGen Pharma Ltd. up in a year?
- 3 of the 8 full years since 2018 were positive — about 38% of the time.
More on UroGen Pharma Ltd.
Annual returns for: S&P 500 · S&P 500 Equal Weight · US Stock Market · Nasdaq-100